Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Robertson

Showing results (501-510 of 565) with videos related to

Pageof 57
Sort By:
Nature Medicine|July 22, 2009
Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humansKara L O'Brien, Jinyan Liu, Sharon L King, et al.
Journal of Gastroenterology and Hepatology|February 20, 2019
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infectionLai Wei, Hiromitsu Kumada, Ponni V Perumalswami, et al.
Journal of Medical Primatology|December 11, 1999
Immunization against SIVmne in macaques using multigenic DNA vaccinesS P Mossman, C C Pierce, M N Robertson, et al.
The Journal of Clinical Investigation|December 29, 2011
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccineNicole Frahm, Allan C DeCamp, David P Friedrich, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
Circulation Research|July 14, 2017
ARHGAP18 Protects Against Thoracic Aortic Aneurysm Formation by Mitigating the Synthetic and Proinflammatory Smooth Muscle Cell PhenotypeRenjing Liu, Lisa Lo, Angelina J Lay, et al.
Lancet (London, England)|November 18, 2008
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialSusan P Buchbinder, Devan V Mehrotra, Ann Duerr, et al.
Vaccine|October 13, 2010
Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humansAndrew J Bett, Sheri A Dubey, Devan V Mehrotra, et al.
The Journal of Infectious Diseases|November 26, 2009
Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimensDavid M Asmuth, Elizabeth L Brown, Mark J DiNubile, et al.
Journal of Virology|December 14, 2011
Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccineHuma Qureshi, Zhong-Min Ma, Ying Huang, et al.
Pageof 57

Showing results (501-510 of 565) with videos related to

Sort By:
Pageof 57
Nature Medicine|July 22, 2009
Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humansKara L O'Brien, Jinyan Liu, Sharon L King, et al.
Journal of Gastroenterology and Hepatology|February 20, 2019
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infectionLai Wei, Hiromitsu Kumada, Ponni V Perumalswami, et al.
Journal of Medical Primatology|December 11, 1999
Immunization against SIVmne in macaques using multigenic DNA vaccinesS P Mossman, C C Pierce, M N Robertson, et al.
The Journal of Clinical Investigation|December 29, 2011
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccineNicole Frahm, Allan C DeCamp, David P Friedrich, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
Circulation Research|July 14, 2017
ARHGAP18 Protects Against Thoracic Aortic Aneurysm Formation by Mitigating the Synthetic and Proinflammatory Smooth Muscle Cell PhenotypeRenjing Liu, Lisa Lo, Angelina J Lay, et al.
Lancet (London, England)|November 18, 2008
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialSusan P Buchbinder, Devan V Mehrotra, Ann Duerr, et al.
Vaccine|October 13, 2010
Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humansAndrew J Bett, Sheri A Dubey, Devan V Mehrotra, et al.
The Journal of Infectious Diseases|November 26, 2009
Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimensDavid M Asmuth, Elizabeth L Brown, Mark J DiNubile, et al.
Journal of Virology|December 14, 2011
Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccineHuma Qureshi, Zhong-Min Ma, Ying Huang, et al.
Pageof 57